Kristina Pereverzeva

Prof. Dr. Kristina Pereverzeva

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
AKA. V. Kontsevaya
A. V. Kontsevaya
AKA. M. Kalinina
A. M. Kalinina
SASergey Avdeev
Sergey Avdeev
MAM. V. Agaltsov
M. V. Agaltsov
БДБ. Ю. Джонова
Б. Ю. Джонова
Создание руководства поддержано Советом по терапевтическим наукам отделения клинической медицины Российской академии наук.

2 September 2019 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
MLM. M. Loukianov
M. M. Loukianov
SMS. Yu. Martsevich
S. Yu. Martsevich
ODO. M. Drapkina
O. M. Drapkina
SYSergey S. Yakushin
Sergey S. Yakushin
AVA. N. Vorobyev
A. N. Vorobyev
SBS. A. Boytsov
S. A. Boytsov
Aim. To evaluate an incidence of oral anticoagulants (OAC) administration during longterm follow-up period in patients with atrial fibrillation (AF) enrolled in outpatient and hospital RECVASA registries.Material and methods. 3169 patients with AF were enrolled in outpatient registries RECVASA (Ryazan), RECVASA AF-Yaroslavl and hospital registries RECVASA AF (Moscow, Kursk, Tula), age 70.9±10.7 years, 43.1% men. The incidence of OAC administration was evaluated in hospital and outpatient settings, including longterm follow-up period (2-6 years).Results. OAC were administrated only in 42.2% of cases (1335 from 3169 patients; age 69.1±10.4 years, 43% men), including warfarin (817 patients; 26%) and non-vitamin K antagonist oral anticoagulants (NOAC) – 518 (16%). Patients with permanent and persistant types of AF had lower incidence of OAC administration (43% and 40%) than in cases of paroxysmal type (47.6%, p<0.05), despite of the higher СНА2DS2-VASc risk score (4.69±1.66 and 4.23±1.57 vs 3.81±1.69; р0.05) contrary to the pronounced difference of thromboembolic risk in these groups (6.14±1.34 and 3.77±1.39; р<0.001). The incidence of OAC administration in hospitals (54.1%) was 2.3 times higher than before hospitalization (23.8%) and was 4.1 times higher than in outpatient registries (13.5%). During follow-up period after hospital treatment (2.3±0.9 years) this parameter decreased from 54.1% to 41.2%, but was still 1.8 times higher than before admission to the hospital. After 4 years follow-up in RECVASA (Ryazan) registry we revealed 4.4 times higher incidence of OAC administration compared with enrollment data (4.2% and 18.3%, р<0.0001). This data was confirmed by the information from outpatient medical cards of accidentally generated group (75 from 297 patients survived during follow-up period): 5.3% at baseline and 22.7% six years later.Conclusions. RECVASA registries in 5 regions of Russia revealed low incidence of OAC administration. The risk of thromboembolic events was higher in patients with AF and no OAC administration compared with patients who received OAC. Patients with paroxysmal type of AF received OAC more often than those with permanent type. There were no significant differences of incidence of OAC therapy in patients with and without history of stroke. Both questioning of patients with AF and analysis of medical cards in outpatient clinics revealed higher incidence of OAC administration after 4-6 years of follow-up compared with the stage of enrollment in registries.

10 November 2015 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
SBSergey Boytsov
Sergey Boytsov
MLM. M. Luk’yAnov
M. M. Luk’yAnov
SYSergey S. Yakushin
Sergey S. Yakushin
SMS. Yu. Martsevich
S. Yu. Martsevich
AVA. N. Vorobyov
A. N. Vorobyov
AМArray А. Мосейчук
Array А. Мосейчук
РЕГИСТР КАРДИОВАСКУЛЯРНЫХ ЗАБОЛЕВАНИЙ (РЕКВАЗА): ДИАГНОСТИКА, СОЧЕТАННАЯ СЕРДЕЧНО-СОСУДИСТАЯ ПАТОЛОГИЯ, СОПУТСТВУЮЩИЕ ЗАБОЛЕВАНИЯ И ЛЕЧЕНИЕ В УСЛОВИЯХ РЕАЛЬНОЙ АМБУЛАТОРНО-ПОЛИКЛИНИЧЕСКОЙ ПРАКТИКИ

1 June 2024 in Cardiovascular & Hematological Disorders-Drug Targets
Verified
Journal Article
Closed access
PDF file
SYSergey Yakushin
Sergey Yakushin
AGArzu Arifovna Gurbanova
Arzu Arifovna Gurbanova
KPKristina Pereverzeva
Kristina Pereverzeva
Background: Kounis syndrome is defined as a combination of acute coronary syndrome and allergic reactions. Objective: In this review, we aim to describe the etiological, clinical, and diagnostic characteristics of Kounis syndrome. Methods: A literature search using PubMed was conducted for the past 32 years using keywords, resulting in the selection of 761 scientific papers. From these, 217 articles describing 235 clinical cases were selected. Patients under 18 years of age or without a confirmed diagnosis were excluded. Results: Among the 235 patients, type I Kounis syndrome was observed in 49.7%, type II in 27.2%, type III in 5.9%, and a combination of types I and II in 1.0%; in 16.2%, it was not possible to classify the type of Kounis syndrome. The median age was 57 years, and 68.5% of the patients were male. The most common causes were antibiotics (32.3%) and non-steroidal anti-inflammatory drugs (24.3%). The clinical features included chest pain (59.1%), hypotension (74.2%), itching (30.6%), and dyspnea (30.6%). Electrocardiographic monitoring revealed ST-segment elevation in 42.9% and was normal in only 5.5% of patients. Coronary angiography was performed in 80.4% of the patients, revealing unchanged coronary arteries in 50.3% of cases. Сonclusion: Allergic myocardial infarction is a serious complication of drug therapy.

23 November 2015 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
SBSergey Boytsov
Sergey Boytsov
МLМ. М. Lukyanov
М. М. Lukyanov
SYSergey S. Yakushin
Sergey S. Yakushin
SMS. Yu. Martsevich
S. Yu. Martsevich
AVA. N. Vorobyev
A. N. Vorobyev
AКArray В. Кудряшов
Array В. Кудряшов
АМБУЛАТОРНО-ПОЛИКЛИНИЧЕСКИЙ РЕГИСТР РЕКВАЗА: ДАННЫЕ ПРОСПЕКТИВНОГО НАБЛЮДЕНИЯ, ОЦЕНКА РИСКА И ИСХОДЫ У БОЛЬНЫХ С КАРДИОВАСКУЛЯРНЫМИ ЗАБОЛЕВАНИЯМИ

28 February 2022 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
KPKristina Pereverzeva
Kristina Pereverzeva
MLM. M. Lukyanov
M. M. Lukyanov
EAE. Yu. Andreenko
E. Yu. Andreenko
VKV. G. Klyashtorny
V. G. Klyashtorny
EPE. A. Pravkina
E. A. Pravkina
SYS. S. Yakushin
S. S. Yakushin
Aim      To determine the factors that influence the long-term prognosis in patients after myocardial infarction (MI) as a part of the prospective REGistry of pATients after myocArdial infarction (REGATA). Material and methods  In 2012–2013, 481 post-myocardial infarction patients were included into the REGATA registry; 247 (51.4 %) were men, median age 72 [62; 78] years. The median duration of prospective follow-up after the inclusion into the registry was 6.1 [4.0–6.6] years. Data were obtained for 474 (98.5 %) patients. Statistical analysis was performed with the Microsoft Excel 2010, StatsoftStatistica10.0 software and partially manually by formulas. Methods of descriptive statistics were used. For quantitative variables with normal distribution, mean values and standard deviations were calculated; intergroup differences were evaluated with Student’s t-test. Differences between groups of survived and deceased patients were evaluated with a nonparametric method using the Pearson’s chi-squared test with a Yates's correction, and the Fisher’s exact test. When the frequency of absent data for the studied variable exceeded 20 %, this variable was not included into the analysis. The 6-year survival was analyzed by the Kaplan-Meier method. Fatal outcomes were analyzed with the Cox proportional hazards regression model. Differences were considered significant at p<0.05. Results During the follow-up period, there were 200 (41.6 %) cases of all-cause death and 123 (25.6 %) cases of cardiovascular death; 39 (8.1 %) of patients had acute cerebrovascular disease (ACVD) and 36 (7.5 %) had recurrent myocardial infarction. The median time from the inclusion into the registry to death was 3.4 [1.6; 5.1] years. A higher risk of all-cause death was significantly associated with factors of age (one-year relative risk, RR, 1.03; 95 % confidence interval, CI, 1.02–1.05; р<0.001), III-IV functional class angina (RR, 1.76; 95 % CI, 1.22–2.53; p=0.003), history of ACVD (RR, 2.12; 95 % CI, 1.50–2.98; p<0.001), atrial fibrillation (AF) (RR, 1.52; 95 % CI, 1.10–2.12; р=0.01), diabetes mellitus (DM) (RR, 1.53; 95 % CI, 1.11–2.10; p=0.009), chronic obstructive pulmonary disease (COPD) (RR, 1.77; 95 % CI, 1.20–2.62; p=0.004), and reduced hemoglobin (RR, 2.09; 95 % CI, 1.31–3.33; p=0.002). A lower risk of death was associated with administration of antiplatelets (RR, 0.57; 95 % CI, 0.37–0.89; p=0.01), angiotensin-converting enzyme (ACE) inhibitors /angiotensin II receptor blockers (ARB) (RR, 0.51; 95 % CI, 0.33–0.78; p=0.002), and statins (RR, 0.48; 95 % CI, 0.34–0.67; p<0.001). A higher risk of nonfatal stroke during the follow-up was significantly associated with age (one-year RR, 1.05; 95 % CI, 1.01–1.09; р=0.02), history of ACVD (RR, 2.74; 95 % CI, 1.33–5.63; p=0.006), and DM (RR, 2.43; 95 % CI, 1.17–5.06; p=0.02), and a higher risk of nonfatal stroke was significantly associated with a history of ACVD (RR, 1.70; 95 % CI, 1.44–2.01; p<0.001), DM (RR, 2.33; 95 % CI, 1.13–4.84; p=0.02), and COPD (RR, 2.47; 95 % CI, 1.02–6.00; p=0.06). Conclusion      In the outpatient REGATA registry that included patients with MI at any previous time, the death rate for 6 years of follow-up was 41.6 %. In 61.5 % of cases, death was caused by cardiovascular diseases. In clinical practice in long-term, a higher risk of unfavorable outcome was associated with old age, III-IV functional class angina, a history of ACVD, AF, DM, and COPD while a lower risk was associated with the administration of antiplatelets, ACE inhibitors/ARB, and statins.